Clinical Trial

Remodeling of MHC-related Immune Microenvironment in MIBC After Neoadjuvant Therapy

Not Yet Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated February 27, 2026 (before its estimated May 15, 2026 completion). Its status may not reflect the trial's current state.
Summary
In this study, the relevant biomarkers for predicting the efficacy of neoadjuvant therapy in patients with MIBC were further explored. Meanwhile, the dynamic molecular monitoring of neoadjuvant therapy in MIBC patients and the treatment guidance based on the MHC tumor immune microenvironment were also explored to select the treatment plan based on relevant biomarkers for subsequent immunotherapy in MIBC patients.
Trial Details
NCT Number NCT07440901
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Muscle-invasive Bladder Cancer
Enrollment 30 participants
Start Date 2026-02-01
Primary Completion 2026-05-15 (estimated)
Study Completion 2027-05-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-27